Application of non-invasive prenatal testing for the screening of fetal chromosomal abnormalities in 12 085 cases.
10.3760/cma.j.cn511374-20190930-00503
- Author:
Luming WANG
1
;
Chiyan ZHOU
;
Yue HU
;
Yuxia JIN
;
Xiaodan LIU
Author Information
1. Prenatal Diagnosis Center, Jiaxing Maternity and Child Health Care Hospital, Jiaxing, Zhejiang 314051, China. 80liuxiaodan@163.com.
- Publication Type:Journal Article
- From:
Chinese Journal of Medical Genetics
2020;37(10):1069-1073
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the value of non-invasive prenatal testing (NIPT) for the screening of fetal chromosomal abnormalities.
METHODS:For 12 085 pregnant women, the results of NIPT and invasive prenatal diagnosis were compared.
RESULTS:The test was successful in 12 067 cases and has detected 179 chromosomal abnormalities, with a positive rate of 1.48%, sensitivity of 98.39% and specificity of 99.02%. Invasive prenatal diagnosis was performed for 3 of 18 patients who had failed NIPT but has detected no karyotypic abnormality. Except for one case of twin Cesarean section which delivered a normal female fetus and a stillbirth of unknown sex, the remainder of the 18 cases all had a normal delivery. The positive rate of NIPT screening for the abnormal ultrasound group was significant higher than that other groups (P< 0.01). Among those with positive results of NIPT, 122 underwent invasive prenatal diagnosis, and 25 trisomy 21, 7 trisomy 18, 3 trisomy 13, 4 aneuploidies of other autosomes, 13 sex chromosomal aneuploidies and 9 microdeletion/microduplications were confirmed, which yielded a positive predictive rate of 86.21%, 50.00%, 23.08%, 21.05%, 46.43%, and 47.36%, respectively.
CONCLUSION:NIPT has high sensitivity, specificity and positive predictive value, and is an effective method for prenatal screening. In addition to chromosomes 21, 18 and 13, NIPT has certain predictive value for other autosomal aneuploidies, sex chromosomal aneuploidies, microdeletion/microduplications, and can provide a reference for karyotype analysis and chromosomal microarray verification.
